Search

Your search keyword '"OVERALL survival"' showing total 5 results
Start Over Descriptor "OVERALL survival" Topic therapeutic use of antineoplastic agents Publication Year Range Last 50 years Database Academic Search Index Publisher mjh life sciences
5 results on '"OVERALL survival"'

1. Clinical Updates: PROSTATE CANCER. Darolutamide delays time to progression from mHSPC to mCRPC vs placebo.

Author

SAYLOR, BENJAMIN P.

Subjects
*THERAPEUTIC use of antineoplastic agents, *DOCETAXEL, *ANTIANDROGENS, *CASTRATION-resistant prostate cancer, *PLACEBOS, *PROSTATE tumors, *TREATMENT effectiveness, *METASTASIS, *DISEASE progression, *OVERALL survival
Abstract

The article focuses on the results of the phase three ARASENS trial on the effectiveness of darolutamide as a treatment in patients with metastatic hormone-sensitive prostate cancer, which were presented at the 2024 American Society of Clinical Oncology Annual Meeting held in Chicago, Illinois. Topics discussed include the improvementin the overall survival and delay time to progression to metastatic castration-resistant disease, and the definition of postprogression survival.

Published
2024

2. Clinical Updates: PROSTATE CANCER. Survival may be improving in de novo mHSPC, new data suggest.

Author

CLARKE, HANNAH

Subjects
*THERAPEUTIC use of antineoplastic agents, *PROSTATE tumors, *EVALUATION of medical care, *CANCER patients, *METASTASIS, *HORMONE therapy, *OVERALL survival, *TIME, *COMORBIDITY
Abstract

The article focuses on a study which shows an improvement in the overall survival (OS) among patients with de novo metastatic hormone-sensitive prostate cancer in clinical practice in the U.S. from 2000 to 2019, which references a research paper by Martin Schoen et al., published in an issue of the "JAMA Network Open." Topics discussed include the median OS in patients younger than 70 years, and the significant role of combination therapy in this improvement.

Published
2024

3. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.

Author

Joszt, Laura

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *LUNG cancer, *DISEASE progression, *EVALUATION of human services programs, *COMBINATION drug therapy, *EPIDERMAL growth factor receptors, *LUNG tumors, *CHEMORADIOTHERAPY, *MEDICAL care research, *TUMOR classification, *TREATMENT effectiveness, *CANCER patients, *ANAPLASTIC lymphoma kinase, *SURVIVAL analysis (Biometry), *QUALITY of life, *PROGRESSION-free survival, *IMMUNOTHERAPY, *PATIENT safety, *OVERALL survival, *CHEMICAL inhibitors
Abstract

The article reports on the results of the 3 EMPOWER-Lung 3 study that were presented at the 2023 European Society for Medical Oncology Congress, showing that cemiplimab plus chemotherapy showed better favorable survival benefits and patient-reported outcomes (PRO) in patients with advanced non-small cell lung cancer (NSCLC). Also cited are the median overall survival (OS), objective response rate (ORR), and progression-free survival (PFS) study results.

Published
2023

4. Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer.

Author

Ryan, Chris

Subjects
*THERAPEUTIC use of antineoplastic agents, *DISEASE progression, *CARBOPLATIN, *CHEMORADIOTHERAPY, *PROGRESSION-free survival, *PACLITAXEL, *INDUCTION chemotherapy, *OVERALL survival, CERVIX uteri tumors
Abstract

The article reports on the results of the phase 3 INTERLACE trial showing that induction chemotherapy followed by chemoradiation lowered by 35% the risk of disease progression or death as compared to chemoradiation alone in patients with locally advanced cervical cancer. According to lead study author Mary McCormack, induction chemotherapy with paclitaxel and carboplatin should be considered as a standard treatment.

Published
2023

5. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.

Author

ROSA, KRISTI

Subjects
*THERAPEUTIC use of antineoplastic agents, *RENAL cell carcinoma, *DRUG efficacy, *PATIENT aftercare, *COMBINATION drug therapy, *COLLEGE teacher attitudes, *TREATMENT effectiveness, *BENZAMIDE, *PROGRESSION-free survival, *OVERALL survival, *THERAPEUTICS
Abstract

The article discusses results from an analysis of the phase three KEYNOTE-426 trial on the efficacy of a combination treatment with pembrolizumab and axitinib, compared with single agent sunitinib, in patients with clear cell renal cell carcinoma (CCRCC). The study evaluated overall survival, progression-free survival, overall response rate, complete response rate, partial response rare, stable disease rate in patients who received pembrolizumab/axitinib and those administered with sunitinib.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results